Top View
- January 24Th, 2020 Release Highlights
- Peptides and Small Molecules Blocking the CXCR4/CXCL12 Axis Overcome Bone Marrow‑Induced Chemoresistance in Acute Leukemias
- Chemokine Receptor Crystal Structures: What Can Be Learnt from Them?
- Mozobil (Plerixafor) Effective Date Begin: March 4, 2009 Effective Date End: Original Date: March 4, 2009 Review Date(S): March 3, 2010 March 4, 2009
- Plerixafor Enables Safe, Rapid, Efficient Mobilization of Hematopoietic Stem Cells in Sickle Cell Disease Patients After Exchang
- CLINICAL the Value of Specialty Pharmaceuticals– a Systematic Review
- Pharmacology Review(S) Memorandum
- Premium Value
- Oncology Comprehensive Drug List Krogerspecialtypharmacy.Com
- Pharmaabkommen A1 E
- Protein Interface of Chemokine Receptor CXCR4
- Mozobil® (Plerixafor)
- MOZOBIL (Plerixafor) RATIONALE for INCLUSION in PA PROGRAM
- Neutrophils in the Era of Immune Checkpoint Blockade
- Mozobil) Reference Number: CP.PHAR.323 Effective Date: 03.01.17 Last Review Date: 08.19 Coding Implications Line of Business: Commercial, HIM, Medicaid Revision Log
- Biased Action of the CXCR4-Targeting Drug Plerixafor Is Essential for Its Superior Hematopoietic Stem Cell Mobilization
- Pathway and Mechanism of Drug Binding to Chemokine Receptors Revealed by Accelerated Molecular Simulations
- Immunology and Inflammation
- Mandatory Specialty Drug List
- Targeting Oncoimmune Drivers of Cancer Metastasis
- Pancreatic Cancer and Immune Checkpoint Inhibitors—Still a Long Way to Go
- Prior Authorization List for Drugs
- CCR5 and the Blood Brain Barrier During HIV-1 Infection and Cell-Cell Communications" (2015)
- Mozobil (Plerixafor) Injection Label
- Specialty Drug List
- Amendment #6.1, Version: October 26, 2015 IRB Number: 1005011049
- Theranostics Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases
- Combined Phytochemistry and Chemotaxis Assays for Identification and Mechanistic Analysis of Anti- Inflammatory Phytochemicals in Fallopia Japonica
- Annex I Summary of Product Characteristics
- WO 2018/045144 Al 08 March 2018 (08.03.2018) W !P O PCT
- Evolving Therapies for Liver Fibrosis
- DRUG NAME: Plerixafor
- Standard Specialty PA and QL List October 2014
- Targeting the CXCR4– CXCL12 Axis—Untapped Potential in the Tumor Microenvironment Stefania Scala
- Do Not Tube List
- Co-Receptor Signaling in the Pathogenesis of Neurohiv
- Concept ID Name Class 1319998 Acebutolol Adrenergics 1154343
- CXCR4 Antagonist AMD3100 (Plerixafor) Modulates Immune Responses in the Tumor Microenvironment
- WHO Drug Information Vol
- Blue Cross Medicare Advantage: Medical Oncology Code List
- MOZOBIL (Plerixafor) Injection, Solution for Subcutaneous Use • Tumor Cell Mobilization in Leukemia Patients: Mozobil May Mobilize Initial U.S
- Specialty Drug List
- Annexes to the Annual Report of the European Medicines Agency 2020
- CCR5/CXCR4 Dual Antagonism for the Improvement of HIV Infection Therapy
- Injectable Drugs Requiring Prior Authorization
- Effectiveness of AMD3100 in Treatment of Leukemia and Solid
- Phase I/II Study of Local Field Irradiation and Temozolomide Followed by Continuous Infusion Plerixafor As an Upfront Therapy for Newly Diagnosed Glioblastoma GBM